Disproportionality analysis of cardiac adverse events associated with lenvatinib using the Japanese Adverse Drug Event Report database
We focused on cardiac AEs associated with lenvatinib as post-marketing AEs. Serious outcomes can arise after lenvatinib administration. Patients should be monitored for signs of onset of these AEs not only at the start of administration, but also over an extended period.
Authors
- Sakura Kobayashi
- Asuka Kojima
- Haruka Wakabayashi
- Yuko Kanbayashi (ORCID: https://orcid.org/0000-0002-0095-2293)
- Tadashi Shimizu (ORCID: https://orcid.org/0000-0002-5563-6730)
- Mayako Uchida (ORCID: https://orcid.org/0000-0003-0507-7309)
Institutions
- Hyogo University of Health Sciences (JP)
- Kobe Medical Center (JP)
- Kobe University (JP)
- Doshisha Women's College of Liberal Arts (JP)
- Hyogo University (JP)
- Osaka University of Pharmaceutical Sciences (JP)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2024-09-02
- DOI
- https://doi.org/10.1111/bcp.16237
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- Taiho Pharmaceutical